Literature DB >> 34605821

A Reporter Based Cellular Assay for Monitoring Splicing Efficiency.

Jason Wong1, William Martelly1, Shalini Sharma2.   

Abstract

During gene expression, the vital step of pre-mRNA splicing involves accurate recognition of splice sites and efficient assembly of spliceosomal complexes to join exons and remove introns prior to cytoplasmic export of the mature mRNA. Splicing efficiency can be altered by the presence of mutations at splice sites, the influence of trans-acting splicing factors, or the activity of therapeutics. Here, we describe the protocol for a cellular assay that can be applied for monitoring the splicing efficiency of any given exon. The assay uses an adaptable plasmid encoded 3-exon/2-intron minigene reporter, which can be expressed in mammalian cells by transient transfection. Post-transfection, total cellular RNA is isolated, and the efficiency of exon splicing in the reporter mRNA is determined by either primer extension or semi-quantitative reverse transcriptase-polymerase chain reaction (RT-PCR). We describe how the impact of disease associated 5' splice-site mutations can be determined by introducing them in the reporter; and how the suppression of these mutations can be achieved by co-transfection with U1 small nuclear RNA (snRNA) construct carrying compensatory mutations in its 5' region that basepairs with the 5'-splice sites at exon-intron junctions in pre-mRNAs. Thus, the reporter can be used for the design of therapeutic U1 particles to improve recognition of mutant 5' splice-sites. Insertion of cis-acting regulatory sites, such as splicing enhancer or silencer sequences, into the reporter can also be used to examine the role of U1 snRNP in regulation mediated by a specific alternative splicing factor. Finally, reporter expressing cells can be incubated with small molecules to determine the effect of potential therapeutics on constitutive pre-mRNA splicing or on exons carrying mutant 5' splice sites. Overall, the reporter assay can be applied to monitor splicing efficiency in a variety of conditions to study fundamental splicing mechanisms and splicing-associated diseases.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34605821      PMCID: PMC8643280          DOI: 10.3791/63014

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.424


  20 in total

1.  NanoDrop microvolume quantitation of nucleic acids.

Authors:  Philippe Desjardins; Deborah Conklin
Journal:  J Vis Exp       Date:  2010-11-22       Impact factor: 1.355

2.  Disease-causing variants of the conserved +2T of 5' splice sites can be rescued by engineered U1snRNAs.

Authors:  Daniela Scalet; Iva Maestri; Alessio Branchini; Francesco Bernardi; Mirko Pinotti; Dario Balestra
Journal:  Hum Mutat       Date:  2018-11-19       Impact factor: 4.878

3.  Sequence contexts that determine the pathogenicity of base substitutions at position +3 of donor splice-sites.

Authors:  Sandie Le Guédard-Méreuze; Christel Vaché; Nicolas Molinari; Julie Vaudaine; Mireille Claustres; Anne-Françoise Roux; Sylvie Tuffery-Giraud
Journal:  Hum Mutat       Date:  2009-09       Impact factor: 4.878

4.  Splice-switching small molecules: A new therapeutic approach to modulate gene expression.

Authors:  Andrea Taladriz-Sender; Emma Campbell; Glenn A Burley
Journal:  Methods       Date:  2019-06-14       Impact factor: 3.608

5.  Exon repression by polypyrimidine tract binding protein.

Authors:  Batoul Amir-Ahmady; Paul L Boutz; Vadim Markovtsov; Martin L Phillips; Douglas L Black
Journal:  RNA       Date:  2005-05       Impact factor: 4.942

Review 6.  RNA mis-splicing in disease.

Authors:  Marina M Scotti; Maurice S Swanson
Journal:  Nat Rev Genet       Date:  2015-11-23       Impact factor: 53.242

7.  Denaturing urea polyacrylamide gel electrophoresis (Urea PAGE).

Authors:  Heike Summer; René Grämer; Peter Dröge
Journal:  J Vis Exp       Date:  2009-10-29       Impact factor: 1.355

8.  Use of modified U1 small nuclear RNA for rescue from exon 7 skipping caused by 5'-splice site mutation of human cathepsin A gene.

Authors:  Naoshi Yamazaki; Keisuke Kanazawa; Maria Kimura; Hironobu Ike; Makiko Shinomiya; Shouko Tanaka; Yasuo Shinohara; Noriaki Minakawa; Kohji Itoh; Yoshiharu Takiguchi
Journal:  Gene       Date:  2018-07-24       Impact factor: 3.688

Review 9.  The pathobiology of splicing.

Authors:  Amanda J Ward; Thomas A Cooper
Journal:  J Pathol       Date:  2010-01       Impact factor: 7.996

10.  Inhibiting expression of specific genes in mammalian cells with 5' end-mutated U1 small nuclear RNAs targeted to terminal exons of pre-mRNA.

Authors:  Puri Fortes; Yolanda Cuevas; Fei Guan; Peng Liu; Sara Pentlicky; Stephen P Jung; Maria L Martínez-Chantar; Jesús Prieto; David Rowe; Samuel I Gunderson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-25       Impact factor: 12.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.